|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Supplementary Table 1: Observed complications from 30 to 90 days post-surgery with regards to the affected organsystem. | | | | |
| **Complication** | **Overall**  **na**  **(%1; %2)** | **NMIBC**  **na**  **(%1; %2)** | **MIBC**  **na**  **(%1; %2)** | **P-Value** |
| **Follow-up information** |  |  |  |  |
| Complete follow-up | 232 (44.5) | 58 (47.2) | 174 (43.7) |  |
| Follow-up <90d | 247 (47.4) | 57 (46.2) | 190 (47.7) |  |
| Not available | 42 (8.1) | 8 (6.5) | 34 (8.5) |  |
| **Complication y/n, na (%)** | 125  (53.9; 24) | 36  (62.1; 29.3) | 89  (51.1; 22.4) | 0.110 |
| **Urogenital complications** |  |  |  |  |
| Urogenital complications y/n, na (%) | 42  (18,1; 8,1) | 10  (17.2; 8.1) | 32  (18.4; 8) | 0.844 |
| Amount (n/patient), median (IQR) | 1 (1-1) | 1 (1-1) | 1 (1-1) | 0.559 |
| Acute renal insufficiency, na (%) | 7  (3; 1.3) | 1  (1.7; 0.8) | 6  (3.4; 1.5) | 0.684 |
| Hydronephrosis, na (%) | 35  (15.1; 6.7) | 9  (15.5; 7.3) | 26  (15; 6.5) | 0.928 |
| Erectile dysfunction, na (%) | 5  (2.2; 1) | 1  (1.7; 0.8) | 4  (2.3; 1) | 1.000 |
| Urolithiasis, na (%) | 1  (0.4; 0.2) | 1  (1.7; 0.8) | 0  (0; 0) | 0.250 |
| **Infectious complications** |  |  |  |  |
| Infectious complications y/n, na (%) | 67  (28.9; 12.9) | 18  (31; 14.6) | 49  (28.2; 12.3) | 0.676 |
| Amount (n/patient), median (IQR) | 1 (1-1) | 1 (1-1) | 1 (1-2) | 0.208 |
| Urinary tract infection, na (%) | 59  (25.4; 11.3) | 16  (27.6; 13) | 43  (24.7; 10.8) | 0.663 |
| Urosepsis, na (%) | 8  (3.4; 1.5) | 1  (1.7; 0.8) | 7  (4; 1.8) | 0.683 |
| Pyonephrosis, na (%) | 13  (5.6; 2.5) | 2  (3.4; 1.6) | 11  (6.3; 2.8) | 0.526 |
| Abscess, na (%) | 1  (0.4; 0.2) | 0  (0; 0) | 1  (0.6; 0.3) | 1.000 |
| **Metabolic complications** |  |  |  |  |
| Metabolic complications y/n, na (%) | 47  (20.3; 9) | 18  (31; 14.6) | 29  (16.7; 7.3) | **0.018\*** |
| Amount (n/patient), median (IQR) | 1 (1-1) | 1 (1-1) | 1 (1-1) | 1.000 |
| Absorption disorders, na (%) | 47  (20.3; 9) | 18  (31; 14.6) | 29  (16.7; 7.3) | **0.018\*** |
| **Complications affecting the urinary diversion** |  |  |  |  |
| Complications affecting the urinary diversion, na (%) | 39  (16.8; 7.5) | 15  (25.9; 12.2) | 24  (13.8; 6) | **0.033\*** |
| Amount (n/patient), median (IQR) | 1 (1-1) | 1 (1-2) | 1 (1-1) | **0.006\*** |
| Conduit stenosis, na (%) | 2  (0.9; 0.4) | 2  (3.4; 1.6) | 0  (0; 0) | 0.062 |
| Conduit prolaps, na (%) | 4  (1.7; 0.8) | 0  (0; 0) | 4  (2.3; 1) | 0.574 |
| Bladder neck constriction, na (%) | 7  (3; 1.3) | 4  (6.9; 3.3) | 3  (1.7; 0.8) | 0.068 |
| Stenosis of the Pouch-nipple, na (%) | 2  (0.9; 0.4) | 2  (3.4; 1.6) | 0  (0; 0) | 0.062 |
| Ureteroenteral stricture, na (%) | 9  (3.9; 1.7) | 2  (3.4; 1.6) | 7  (4; 1.8) | 1.000 |
| Vesicoureteral reflux, na (%) | 1  (0.4; 0.2) | 1  (1.7; 0.8) | 0  (0; 0) | 0.250 |
| Stress incontinence, na (%) | 13  (5.6; 2.5) | 5  (8.6; 4.1) | 8  (4.6; 2) | 0.320 |
| Urethral stricture, na (%) | 4  (1.7; 0.8) | 3  (5.2; 2.4) | 1  (0.6; 0.3) | **0.049\*** |
| Urinary retention, na (%) | 7  (3; 1.3) | 4  (6.9; 3.3) | 3  (1.7; 0.8) | 0.068 |
| **Surgical complications** |  |  |  |  |
| Surgical complication y/n, na (%) | 42  (18.1; 8.1) | 13  (22.4; 10.6) | 29  (16.7; 7.3) | 0.325 |
| Amount (n/patient), median (IQR) | 1 (1-1) | 1 (1-1) | 1 (1-1) | 0.893 |
| Parastomal hernia, na (%) | 28  (12.1; 5.4) | 11  (19; 8.9) | 17  (9.8; 4.3) | 0.063 |
| Fistula, na (%) | 4  (1.7; 0.8) | 0  (0; 0) | 4  (2.3; 1) | 0.574 |
| Lymphocele, na (%) | 3  (1.3; 0.6) | 1  (1.7; 0.8) | 2  (1.1; 0.5) | 1.000 |
| Bowel obstruction / Ileus, na (%) | 12  (5.2; 2.3) | 2  (3.4; 1.6) | 10  (5.7; 2.5) | 0.735 |
| Intestinal anastomotic leak, na (%) | 1  (0.4; 0.2) | 1  (1.7; 0.8) | 0  (0; 0) | 0.250 |
| **Highest complication according to CDC** |  |  |  | 0.493 |
| CDC grade I, na (%) | 13  (5.6; 2.5) | 5  (8.6; 4.1) | 8  (4.5; 2) |  |
| CDC grade II, na (%) | 50  (21.6; 9.6) | 15  (25.9; 12.2) | 35  (20.1; 8.8) |  |
| CDC grade IIIa, na (%) | 2  (0.9; 0.4) | 1  (1.7; 0.8) | 1  (0.6; 0.3) |  |
| CDC grade IIIb, na (%) | 64  (27.6; 12.3) | 18  (31; 14.6) | 46  (26.4; 11.6) |  |
| CDC grade IVa, na (%) | 0  (0; 0) | 0  (0; 0) | 0  (0; 0) |  |
| CDC grade IVb, na (%) | 0  (0; 0) | 0  (0; 0) | 0  (0; 0) |  |
| CDC grade V, na (%) | 1  (0.4; 0.2) | 0  (0; 0) | 1  (0.6; 0.3) |  |
| **Total number of complications (n/patient), median (IQR)** | 2 (1-3) | 2 (1-3) | 2 (1-3) | 0.052 |
| **Revision surgery** |  |  |  |  |
| Revision surgery y/n, na (%) | 64  (27.6; 12.3) | 18  (31; 14.6) | 46  (26.4; 11.6) | 0.577 |
| Amount (n/patient), median (IQR) | 2 (1-3) | 2 (1-2) | 2 (1-3) | 0.447 |
| Ureterocystoneostomy, na (%) | 6  (2.6; 1.2) | 3  (5.2; 2.4) | 3  (1.7; 0.8) | 0.176 |
| Hernia / Ileus / Lymphocele / Fistula, na (%) | 25  (10.8; 4.8) | 10  (17.2; 8.1) | 15  (8.6; 3.8) | 0.079 |
| Incision urethra / bladder neck, na (%) | 8  (3.4; 1.5) | 4  (6.9; 3.2) | 4  (2.3; 1) | 0.118 |
| Urinary diversion, na (%) | 8  (3.4; 1.5) | 1  (1.7; 0.8) | 7  (4; 1.8) | 0.683 |
| Nephrostomy / ureteral stent, na (%) | 27  (11.6; 5.2) | 4  (6.9; 3.3) | 23  (13.2; 5.8) | 0.174 |
| Revision due to persistent incontinence, na (%) | 5  (2.2; 1) | 3  (5.2; 2.4) | 2  (1.1; 0.5) | 0.107 |
| \* Indicates statistical significance. | | | | |
| a Numbers reflect the number of patients. | | | | |
| 1 Numbers reflect percentages with regards to patients with full follow-up. | | | | |
| 2 Numbers reflect percentages with regards to the overall population. | | | | |
| NMIBC = non-muscle-invasive Bladder Cancer, MIBC = muscle-invasive Bladder Cancer, IQR = Interquartile Range, CDC = Clavien-Dindo-Classification. | | | | |